Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Leiomyoma 2Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2 1Uterine Hemorrhage 1Prostatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Cushing Syndrome 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1ACTH Syndrome, Ectopic 1

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 26Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × Mifepristone × Clear all
NCT00140478 2009-12-09

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
48 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡